Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 705

1.

Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.

Chen JJ, Swope DM, Dashtipour K.

Clin Ther. 2007 Sep;29(9):1825-49. Review.

PMID:
18035186
[PubMed - indexed for MEDLINE]
2.

Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.

Guay DR.

Am J Geriatr Pharmacother. 2006 Dec;4(4):330-46. Review.

PMID:
17296539
[PubMed - indexed for MEDLINE]
3.

Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease.

Chen JJ, Ly AV.

Am J Health Syst Pharm. 2006 May 15;63(10):915-28. Review.

PMID:
16675649
[PubMed - indexed for MEDLINE]
4.

Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease.

Chen JJ, Swope DM.

J Clin Pharmacol. 2005 Aug;45(8):878-94. Review.

PMID:
16027398
[PubMed - indexed for MEDLINE]
5.

Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline.

Youdim MB, Maruyama W, Naoi M.

Drugs Today (Barc). 2005 Jun;41(6):369-91. Review.

PMID:
16110345
[PubMed - indexed for MEDLINE]
6.

Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.

Fernandez HH, Chen JJ.

Clin Neuropharmacol. 2007 May-Jun;30(3):150-68. Review.

PMID:
17545750
[PubMed - indexed for MEDLINE]
7.

Rasagiline: a review of its use in the management of Parkinson's disease.

Oldfield V, Keating GM, Perry CM.

Drugs. 2007;67(12):1725-47. Review.

PMID:
17683172
[PubMed - indexed for MEDLINE]
8.

Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.

Fernandez HH, Chen JJ.

Pharmacotherapy. 2007 Dec;27(12 Pt 2):174S-185S. Review.

PMID:
18041937
[PubMed - indexed for MEDLINE]
9.

Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease.

Hoy SM, Keating GM.

Drugs. 2012 Mar 26;72(5):643-69. doi: 10.2165/11207560-000000000-00000. Review. Erratum in: Drugs. 2012 Apr 16;72(6):870-1.

PMID:
22439669
[PubMed - indexed for MEDLINE]
10.

Rasagiline.

Siddiqui MA, Plosker GL.

Drugs Aging. 2005;22(1):83-91; discussion 93-4. Review.

PMID:
15663351
[PubMed - indexed for MEDLINE]
11.

Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.

Henchcliffe C, Schumacher HC, Burgut FT.

Expert Rev Neurother. 2005 Nov;5(6):811-21. Review.

PMID:
16274338
[PubMed - indexed for MEDLINE]
12.

Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives.

Mandel S, Weinreb O, Amit T, Youdim MB.

Brain Res Brain Res Rev. 2005 Apr;48(2):379-87. Review.

PMID:
15850677
[PubMed - indexed for MEDLINE]
13.

The role of rasagiline in the treatment of Parkinson's disease.

Leegwater-Kim J, Bortan E.

Clin Interv Aging. 2010 May 25;5:149-56. Review.

PMID:
20517484
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.

Weinreb O, Amit T, Bar-Am O, Youdim MB.

Prog Neurobiol. 2010 Nov;92(3):330-44. doi: 10.1016/j.pneurobio.2010.06.008. Epub 2010 Jun 19. Review.

PMID:
20600573
[PubMed - indexed for MEDLINE]
15.

Neuroprotection by rasagiline: a new therapeutic approach to Parkinson's disease?

Blandini F.

CNS Drug Rev. 2005 Summer;11(2):183-94. Review.

PMID:
16007239
[PubMed - indexed for MEDLINE]
16.

Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors.

Chen JJ, Fernandez HH.

Drugs Aging. 2007;24(8):663-80. Review.

PMID:
17702535
[PubMed - indexed for MEDLINE]
17.

Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects.

Schapira AH.

CNS Drugs. 2011 Dec 1;25(12):1061-71. doi: 10.2165/11596310-000000000-00000. Review.

PMID:
22133327
[PubMed - indexed for MEDLINE]
18.

The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge?

Chen JJ, Wilkinson JR.

J Clin Pharmacol. 2012 May;52(5):620-8. doi: 10.1177/0091270011406279. Epub 2011 May 31. Review.

PMID:
21628600
[PubMed - indexed for MEDLINE]
19.

[Rasagiline in monotherapy in patients with early stages of Parkinson's disease and in combined and adjunct therapy to levodopa with moderate and advanced stages].

Pagonabarraga J, Rodríguez-Oroz MC.

Rev Neurol. 2013 Jan 1;56(1):25-34. Review. Spanish.

PMID:
23250679
[PubMed - indexed for MEDLINE]
Free Article
20.

Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition.

Youdim MB, Bar Am O, Yogev-Falach M, Weinreb O, Maruyama W, Naoi M, Amit T.

J Neurosci Res. 2005 Jan 1-15;79(1-2):172-9. Review.

PMID:
15573406
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk